Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLBSOTCMKTS:CTYXOTCMKTS:EMMANASDAQ:GRNV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsCTYXCurative Biotechnology$0.03$0.03$0.00▼$0.22$9.89M-33.993.01 million shs197,414 shsEMMAEmmaus Life Sciences$0.09$0.11$0.05▼$0.34$5.70M1.613,954 shs50 shsGRNVGreenVision Acquisition$10.89$7.70▼$25.30$37K0.07105,738 shs1.54 million shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%CTYXCurative Biotechnology+4.95%-12.86%-9.63%-10.95%+25.13%EMMAEmmaus Life Sciences+0.01%-19.06%-10.58%-7.89%-70.29%GRNVGreenVision Acquisition0.00%0.00%0.00%-57.54%-99.31%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACTYXCurative BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AGRNVGreenVision AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLBSCaladrius BiosciencesN/AN/AN/AN/ACTYXCurative BiotechnologyN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AGRNVGreenVision AcquisitionN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/ACTYXCurative BiotechnologyN/AN/AN/AN/AN/AN/AEMMAEmmaus Life Sciences$18.39M0.31N/AN/A($0.69) per share-0.13GRNVGreenVision AcquisitionN/AN/AN/AN/A$0.70 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/ACTYXCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AEMMAEmmaus Life Sciences-$10.62M-$0.10N/A∞N/A-16.66%N/A-9.73%N/AGRNVGreenVision Acquisition-$510KN/A0.00N/AN/AN/A-54.82%-2.65%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLBSCaladrius BiosciencesN/AN/AN/AN/AN/ACTYXCurative BiotechnologyN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AGRNVGreenVision AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLBSCaladrius BiosciencesN/A22.3322.33CTYXCurative BiotechnologyN/AN/AN/AEMMAEmmaus Life SciencesN/A0.150.12GRNVGreenVision AcquisitionN/A0.290.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLBSCaladrius Biosciences15.57%CTYXCurative BiotechnologyN/AEMMAEmmaus Life Sciences7.42%GRNVGreenVision AcquisitionN/AInsider OwnershipCompanyInsider OwnershipCLBSCaladrius Biosciences2.20%CTYXCurative BiotechnologyN/AEMMAEmmaus Life Sciences35.00%GRNVGreenVision Acquisition42.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableCTYXCurative BiotechnologyN/A388.50 millionN/ANot OptionableEMMAEmmaus Life Sciences5461.85 million40.20 millionNot OptionableGRNVGreenVision AcquisitionN/A3.35 millionN/ANot OptionableGRNV, EMMA, CTYX, and CLBS HeadlinesSourceHeadlineHelbiz IPO (HLBZ) Stockbenzinga.com - August 20 at 6:09 PMSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of GreenVision Acquisition Corp. (Nasdaqfintechzoom.com - August 17 at 1:37 AMScooter-Share Helbiz’s Friday 13th Debut Shows SPAC Refundsfinance.yahoo.com - August 13 at 5:28 PMWhy GreenVision's Stock Is Skyrocketing Todaymsn.com - August 13 at 5:28 PMHelbiz, Inc. and Greenvision Acquisition Corp. Announce Closing of Business Combination; Helbiz to Trade on Nasdaq Under Symbol "HLBZ"finance.yahoo.com - August 13 at 8:04 AMHelbiz Partners with Lightning eMotors to Deploy Electric Vehicles for Fleet Managementfinance.yahoo.com - July 30 at 8:47 AMMicro-Mobility Leader, Helbiz, Launches E-Scooters in Reggio Emilia, Italyfinance.yahoo.com - July 26 at 12:47 PMMedia Sentiment Over TimeCompany DescriptionsCaladrius BiosciencesNASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Curative BiotechnologyOTCMKTS:CTYXCurative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.Emmaus Life SciencesOTCMKTS:EMMAEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.GreenVision AcquisitionNASDAQ:GRNVAs of April 1, 2021, operates as a subsidiary of Helbiz, Inc.. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.